|
BIBLIOGRAFÍA
1 van
Leeuwen
MA, van
Rijswijk
MH, van
der
Heijde
DM et
al.
The
acute-phase
response
in
relation
to
radiographic
progression
in early
rheumatoid
arthritis:a
prospective
study
during
the
first
three
years of
the
disease.
Br J
Rheumatol
1993(32
Suppl
3):9–13.
2 Stenger
AA, van
Leeuwen
MA,
Houtman
PM et
al.
Early
effective
suppression
of
inflammation
in
rheumatoid
arthritis
reduces
radiographic
progression.
Br J
Rheumatol
1998;37:1157–63.
3 van
der
Horst-Bruinsma
IE,
Speyer
I,
Visser
H,
Breedveld
FC,
Hazes JM.
Diagnosis
and
course
of early
onset
arthritis:
results
from a
special
early
arthritis
clinic
compared
to
routine
patient
care. Br
J
Rheumatol
1998;37:1084–8.
4 Kaufmann
J,
Kielstein
V,
Kilian
S, Stein
G, Hein
G.
Relation
between
body
mass
index
and
radiological
progression
in
patients
with
rheumatoid
arthritis.
J
Rheumatol
2003;30:2350–5.
5
Smolen
JS, van
der
Heijde
DM, St
Clair EW
et al.
Active-controlled
study of
patients
receiving
infliximab
for the
treatment
of
rheumatoid
arthritis
of early
onset
(ASPIRE)
study
group.
Predictors
of joint
damage
in
patients
with
early
rheumatoid
arthritis
treated
with
high-dose
methotrexate
with or
without
concomitant
infliximab.
Results
from the
ASPIRE
Trial.
Arthritis
Rheum
2006;54:702–10.
6
Garnero
P,
Geusens
P,
Landewe´
R.
Biochemical
markers
of joint
tissue
turnover
in early
rheumatoid
arthritis.
Clin Exp
Rheumatol
2003;21(5
Suppl
31):S54–8.
7
Tortora
G,
Derrickson
B.
Principles
of
anatomy
and
physiology,
11th edn.
Hoboken,NJ:
John
Wiley
and
Sons,
2006.
8
Takasugi
K,
Yamamura
M,
Iwahashi
M et al.
Induction
of
tumour
necrosis
factor
receptor-expressing
macrophages
by
interleukin-10
and
macrophage
colonystimulating
factor
in
rheumatoid
arthritis.
Arthritis
Res Ther
2006;8:R126.
9
Boers M,
Kostense
PJ,
Verhoeven
AC, van
der
Linden
S. COBRA
Trial
group.Combinatietherapie
Bij
Reumatoide
Artritis.
Inflammation
and
damage
in an
individual
joint
predict
further
damage
in that
joint in
patients
with
early
rheumatoid
arthritis.
Arthritis
Rheum
2001;44:2242–6.
10
Jenkins
JK,
Hardy
KJ,
McMurray
RW. The
pathogenesis
of
rheumatoid
arthritis:
a guide
to
therapy.
Am J Med
Sci
2002;323:171–80.
11
Verstappen
SMM,
Poole
AR,
Ionescu
M et al.
Utrecht
Rheumatoid
Arthritis
Cohort
Study
group (SRU).
Radiographic
joint
damage
in
rheumatoid
arthritis
is
associated
with
differences
in
cartilage
turnover
and can
be
detected
by serum
biomarkers:
an
evaluation
from 1
to 4
years
after
diagnosis.
Arthritis
Res Ther
2006;8:1–9.
12
Roux-Lombard
P,
Eberhardt
K, Saxne
T, Dayer
JM,
Wollheim
FA.
Cytokines,
metalloproteinases,
their
inhibitors
and
cartilage
oligomeric
matrix
protein:
relationship
to
radiological
progression
and
inflammation
in early
rheumatoid
arthritis.
A
prospective
5-year
study.
Rheumatology
2001;40:544–51.
13 Kirwan
JR.
Links
between
radiological
change,
disability,
and
pathology
in
rheumatoid
arthritis.
J
Rheumatol
2001;28:881–6.
14
Emery P.
The
Dunlop-Dottridge
Lecture:
prognosis
in
inflammatory
arthritis:the
value of
HLA
genotyping
and
oncological
analogy.
J
Rheumatol
1997;24:1436–42.
15
Nakamura
RM.
Progress
in the
use of
biochemical
and
biological
markers
for
evaluation
of
rheumatoid
arthritis.
J Clin
Lab Anal
2000;14:305–13.
16
Ronnelid
J, Wick
MC,
Lampa J
et al.
Longitudinal
analysis
of
citrullinated
protein/peptide
antibodies
(anti-CP)
during 5
year
follow
up in
early
rheumatoid
arthritis:anti-CP
status
predicts
worse
disease
activity
and
greater
radiological
progression.
Ann
Rheum
Dis
2005;64:1744–9.
17
Nakamura
RM.
Progress
in the
use of
biochemical
and
biological
markers
for
evaluation
of
rheumatoid
arthritis.
J Clin
Lab Anal
2000;14:305–13.
18
Plant MJ,
Williams
AL,
O’Sullivan
MM,
Lewis
PA,
Coles
EC,
Jessop
JD.
Relationship
between
time-integrated
C-reactive
protein
levels
and
radiological
progression
in
patients
with
rheumatoid
arthritis.
Arthritis
Rheum
2000;43:1473–7.
19
van
Leeuwen
MA, van
Rijswijk
MH,
Sluiter
WJ et
al.
Individual
relationship
between
progression
of
radiological
damage
and the
acute
phase
response
in early
rheumatoid
arthritis.
Towards
development
of a
decision
support
system.
J
Rheumatol
1997;24:20–7.
20
Aman
S,
Paimela
L,
Leirisalo-Repo
M et al.
Prediction
of
disease
progression
in early
rheumatoid
arthritis
by ICTP,
RF and
CRP. A
comparative
3-year
follow-up
study.
Rheumatology
2000;39:1009–13.
21
Jansen
LM, van
Schaardenburg
D, van
der
Horst-Bruinsma
IE,
Bezemer
PD,
Dijkmans
BA.
Predictors
of
functional
status
in
patients
with
early
rheumatoid
arthritis.
Ann
Rheum
Dis
2000;59:223–6.
22
Jansen
LM, van
der
Horst-Bruinsma
IE, van
Schaardenburg
D,
Bezemer
PD,
Dijkmans
BA.
Predictors
of
radiographic
joint
damage
in
patients
with
early
rheumatoid
arthritis.
Ann
Rheum
Dis
2001;60:924–7.
23
Devlin
J, Gough
A,
Huissoon
A et al.
The
acute
phase
and
function
in early
rheumatoid
arthritis.
C-reactive
protein
levels
correlate
with
functional
outcome.
J
Rheumatol
1997;24:9–13.
24
Quinn
MA,
Conaghan
PG,
O’Connor
PJ et
al.
Very
early
treatment
with
infliximab
in
addition
to
methotrexate
in
early,
poor-prognosis
rheumatoid
arthritis
reduces
magnetic
resonance
imaging
evidence
of
synovitis
and
damage,
with
sustained
benefit
after
infliximab
withdrawal:
results
from a
twelve-month
randomized,
double
blind,
placebo-controlled
trial.
Arthritis
Rheum
2005;52:27–35.
25
Landewe´
R, van
der
Heijde
D.
Radiographic
progression
in
rheumatoid
arthritis.
Clin Exp
Rheumatol
2005;23(5
Suppl
39):S63–8.
26
Prevoo
ML,
van’t
Hof MA,
Kuper
HH, van
Leeuwen
MA, van
de Putte
LB, van
Riel PL.
Modified
disease
activity
scores
that
include
twenty-eight-joint
counts.
Arthritis
Rheum
1995;38:44–8.
27
Conaghan
PG,
Quinn
MA,
O’Connor
P,
Wakefield
RJ,
Karim Z,
Emery P.
Can very
high-dose
anti-tumor
necrosis
factor
blockade
at onset
of
rheumatoid
arthritis
produce
long-term
remission?
Arthritis
Rheum
2002;46:1971–2.
28
Charles
P,
Elliott
MJ,
Davis D
et al.
Regulation
of
cytokines,
cytokine
inhibitors,
and
acute-phase
proteins
following
anti-TNF-alpha
therapy
in
rheumatoid
arthritis.
J
Immunol
1999;163:1521–8.
29
Grigor
C,
Capell
H,
Stirlin
A et al.
Effect
of a
treatment
strategy
of tight
control
for
rheumatoid
arthritis
(the
TICORA
study):
a
single-blind
randomized
controlled
trial.
Lancet
2004;364:263–9.
30
Capell
HA,
Madhok
R,
Hunter
JA et
al.
Lack of
radiological
and
clinical
benefit
over two
years of
low dose
prednisolone
for
rheumatoid
arthritis:
results
of a
randomised
controlled
trial.
Annals
of the
Rheumatic
Diseases.
2004;63(7):797–803.
31
Hansen
TM,
Kryger
P,
Elling H
et al.
Double
blind
placebo
controlled
trial of
pulse
treatment
with
methylprednisolone
combined
with
disease
modifying
drugs in
rheumatoid
arthritis.
British
Medical
Journal.
1990;301(6746):268–270.
32
Hickling
P,
Jacoby
RK,
Kirwan
JR et
al.
Joint
destruction
after
glucocorticoids
are
withdrawn
in early
rheumatoid
arthritis.
British
Journal
of
Rheumatology.
1998;37(9):930–936.
33
Kirwan
JR,
Byron M,
Dieppe P
et al.
The
effect
of
glucocorticoids
on joint
destruction
in
rheumatoid
arthritis.
New
England
Journal
of
Medicine.
1995;333(3):142–146.
34
Svensson
B,
Boonen
A,
Albertsson
K et al.
Low-dose
prednisolone
in
addition
to the
initial
diseasemodifying
antirheumatic
drug in
patients
with
early
active
rheumatoid
arthritis
reduces
joint
destruction
and
increases
the
remission
rate: A
two-year
randomized
trial.
Arthritis
&
Rheumatism.
2005;52(11):3360–3370.
35
Van
Everdingen
AA,
Jacobs
JW,
Siewertsz
van
Reesema
DR et
al.
Low-dose
prednisone
therapy
for
patients
with
early
active
rheumatoid
arthritis:
clinical
efficacy,
disease-modifying
properties,
and side
effects:
a
randomized,
double-blind,
placebo-controlled
clinical
trial.
Ann
Intern
Med.
2002;136(1):1–12.
36
Van
Everdingen
AA,
Siewertsz
van
Reesema
DR,
Jacobs
JW et
al.
The
clinical
effect
of
glucocorticoids
in
patients
with
rheumatoid
arthritis
may be
masked
by
decreased
use of
additional
therapies.
Arthritis
&Rheumatism.
2004;51(2):233–238.
37
Wassenberg
S, Rau
R,
Steinfeld
P et al.
Very
low-dose
prednisolone
in early
rheumatoid
arthritis
retards
radiographic
progression
over two
years: A
multicenter,
double-blind,
placebo-controlled
trial.
Arthritis
&
Rheumatism.
2005;52(11):3371–3380.
38
Choy
EH,
Kingsley
GH,
Khoshaba
B et al.
A two
year
randomised
controlled
trial of
intramuscular
depot
steroids
in
patients
with
established
rheumatoid
arthritis
who have
shown an
incomplete
response
to
disease
modifying
antirheumatic
drugs.
Annals
of the
Rheumatic
Diseases.
2005;64(9):1288–1293.
39
Kirwan
JR,
Hallgren
R,
Mielants
H et al.
A
randomised
placebo
controlled
12 week
trial of
budesonide
and
prednisolone
in
rheumatoid
arthritis.
Annals
of the
Rheumatic
Diseases.
2004;63(6):688–695.
40
Van
Vliet-Daskalopoulu
E,
Jentjens
T,
Scheffer
RTC.
Intra-articular
rimexolone
in the
rheumatoid
knee: A
placebo-controlled,
double-blind,
multicentre
trial of
three
doses.
British
Journal
of
Rheumatology.1987;26(6):450–453.
41
Hansen
M,
Podenphant
J,
Florescu
A et al.
A
randomised
trial of
differentiated
prednisolone
treatment
in
active
rheumatoid
arthritis.
Clinical
benefits
and
skeletal
side
effects.
Annals
of the
Rheumatic
Diseases.1999;58(11):713–718.
42
Corkill
MM,
Kirkham
BW,
Chikanza
IC et
al.
Intramuscular
depot
methylprednisolone
induction
of
chrysotherapy
in
rheumatoid
arthritis:
a
24-week
randomized
controlled
trial.
British
Journal
of
Rheumatology.
1990;29(4):274–279.
43
Finckh
A, Liang
MH, van
Herckenrode
CM et
al.
Long-term
impact
of early
treatment
on
radiographic
progression
in
rheumatoid
arthritis:
A
meta-analysis.
Arthritis
&
Rheumatism.
2006;55(6):864–872.
44
Anon. A
randomized
trial of
hydroxychloroquine
in early
rheumatoid
arthritis:
the HERA
Study.
American
Journal
of
Medicine.
1995;98(2):156–168.
45
Tsakona
E,
Fitzgerald
AA.
Consequences
of
delayed
therapy
with
second-line
agents
in
rheumatoid
arthritis:
a 3 year
followup
on the
hydroxychloroquine
in early
rheumatoid
arthritis
(HERA)
study.
Journal
of
Rheumatology.
2000;27(3):623–629.
46
Borg
G,
Allander
E, Lund
B et al.
Auranofin
improves
outcome
in early
rheumatoid
arthritis.
Results
from a
2-year,
double
blind
placebo
controlled
study.
Journal
of
Rheumatology.
1988;15(12):1747–1754.
47
Egsmose
C, Lund
B, Borg
G et al.
Patients
with
rheumatoid
arthritis
benefit
from
early
2nd line
therapy:
5 year
followup
of a
prospective
double
blind
placebo
controlled
study.
Journal
of
Rheumatology.1995;22(12):2208–2213.
48
Mottonen
T,
Hannonen
P,
Korpela
M et al.
Delay to
institution
of
therapy
and
induction
of
remission
using
single-drug
or
combination-disease-modifying
antirheumatic
drug
therapy
in early
rheumatoid
arthritis.
Arthritis
&
Rheumatism.
2002;46(4):894–898.
49
Van
der
Heide A,
Jacobs
JW,
Bijlsma
JW et
al. The
effectiveness
of early
treatment
with
‘second-line’
antirheumatic
drugs. A
randomized,
controlled
trial.
Ann
Intern
Med.
1996;124(8):699–707.
50
Verstappen
SM,
Jacobs
JW,
Bijlsma
JW et
al.
Five-year
followup
of
rheumatoid
arthritis
patients
after
early
treatment
with
disease-modifying
antirheumatic
drugs
versus
treatment
according
to the
pyramid
approach
in the
first
year.
Arthritis
&
Rheumatism.
2003;48(7):1797–1807.
51
Buckland-Wright
JC,
Clarke
GS,
Chikanza
IC et
al.
Quantitative
microfocal
radiography
detects
changes
in
erosion
area in
patients
with
early
rheumatoid
arthritis
treated
with
myocrisine.
Journal
of
Rheumatology.1993;20(2):243–247.
52
Choy
EH,
Scott
DL,
Kingsley
GH et
al.
Treating
rheumatoid
arthritis
early
with
disease
modifying
drugs
reduces
joint
damage:
a
randomised
double
blind
trial of
sulphasalazine
vs
diclofenac
sodium.
Clinical
&
Experimental
Rheumatology.
2002;20(3):351–358.
53
Peltomaa
R,
Paimela
L, Helve
T et al.
Effect
of
treatment
on the
outcome
of very
early
rheumatoid
arthritis.
Scandinavian
Journal
of
Rheumatology.
2001;30(3):143–148.
54
Nell
VP,
Machold
KP,
Eberl G
et al.
Benefit
of very
early
referral
and very
early
therapy
with
diseasemodifying
anti-rheumatic
drugs in
patients
with
early
rheumatoid
arthritis.
Rheumatology.
2004;43(7):
906–914.
55
Van
Aken J,
Lard LR,
Le
Cessie S
et al.
Radiological
outcome
after
four
years of
early
versus
delayed
treatment
strategy
in
patients
with
recent
onset
rheumatoid
arthritis.
Annals
of the
Rheumatic
Diseases.2004;63(3):274–279.
56
Lard
LR,
Visser
H,
Speyer I
et al.
Early
versus
delayed
treatment
in
patients
with
recent-onset
rheumatoid
arthritis:
comparison
of two
cohorts
who
received
different
treatment
strategies.
American
Journal
of
Medicine.
2001;111(6):446–451.
57
Korthals-de
Bos I,
Van
Tulder
M, Boers
M et al.
Indirect
and
total
costs of
early
rheumatoid
arthritis:
a
randomized
comparison
of
combined
step-down
prednisolone,
methotrexate,
and
sulfasalazine
with
sulfasalazine
alone.
Journal
of
Rheumatology.
2004;31(9):1709–1716.
58
Choy
EH,
Smith C,
Dore CJ
et al. A
meta-analysis
of the
efficacy
and
toxicity
of
combining
diseasemodifying
anti-rheumatic
drugs in
rheumatoid
arthritis
based on
patient
withdrawal.
Rheumatology.2005;44(11):1414–1421.
59
Felson
DT,
Anderson
JJ,
Meenan
RF. The
efficacy
and
toxicity
of
combination
therapy
in
rheumatoid
arthritis.
A
meta-analysis.
Arthritis
&
Rheumatism.
1994;37(10):1487–1491.
60
Hetland
ML,
Stengaard-Pedersen
K.
Combination
treatment
with
methotrexate,
cyclosporine,
and
intraarticular
betamethasone
compared
with
methotrexate
and
intraarticular
betamethasone
in early
active
rheumatoid
arthritis:
an
investigator-initiated,
multicenter,
randomized,
double-blind,
parallelgroup,
placebo-controlled
study.
Arthritis
&
Rheumatism.
2006;54(5):1401–1409.
61
Hetland
ML,
Stengaard-Pedersen
K,
Junker P
et al.
Aggressive
combination
therapy
with
intraarticular
glucocorticoid
injections
and
conventional
DMARDs
in early
rheumatoid
arthritis.
Two year
clinical
and
radiographic
results
from the
CIMESTRA
study.
Annals
of the
Rheumatic
Diseases.
2007;66
62
Korpela
M,
Laasonen
L,
Hannonen
P et al.
Retardation
of joint
damage
in
patients
with
early
rheumatoid
arthritis
by
initial
aggressive
treatment
with
disease-modifying
antirheumatic
drugs:
five-year
experience
from the
FIN-RACo
study.
Arthritis
&
Rheumatism.
2004;50(7):2072–2081.
63
Makinen
H,
Kautiainen
H,
Hannonen
P et al.
Sustained
remission
and
reduced
radiographic
progression
with
combination
disease
modifying
antirheumatic
drugs in
early
rheumatoid
arthritis.
Journal
of
Rheumatology.
2007;34(2):316–321.
64
Mottonen
T,
Hannonen
P,
LeirisaloRepo
M et al.
Comparison
of
combination
therapy
with
single-drug
therapy
in early
rheumatoid
arthritis:
A
randomised
trial.
Lancet.
1999;353(9164):1568–1573.
65
Puolakka
K.
Impact
of
initial
aggressive
drug
treatment
with a
combination
of
disease-modifying
antirheumatic
drugs on
the
development
of work
disability
in early
rheumatoid
arthritis:
a
five-year
randomized
followup
trial.
Arthritis
&
Rheumatism.
2004;50(1):55–62.
66
Van
Jaarsveld
CH,
Jacobs
JW, Van
der Veen
MJ et
al.
Aggressive
treatment
in early
rheumatoid
arthritis:
a
randomised
controlled
trial.
On
behalf
of the
Rheumatic
Research
Foundation
Utrecht,
The
Netherlands.
Annals
of the
Rheumatic
Diseases.
2000;59(6):468–477.
67
Boers M.
Randomised
comparison
of
combined
step-down
prednisolone,
methotrexate
and
sulphasalazine
with
sulphasalazine
alone in
early
rheumatoid
arthritis.
Lancet.
1997;350(9074):309–318.
68
Landewe
RB,
Boers M,
Verhoeven
AC et
al.
COBRA
combination
therapy
in
patients
with
early
rheumatoid
arthritis:
long-term
structural
benefits
of a
brief
intervention.
Arthritis
&
Rheumatism.
2002;46(2):347–356.
69
Capell
HA,
Madhok
R,
Porter
DR et
al.
Combination
therapy
with
sulfasalazine
and
methotrexate
is more
effective
than
either
drug
alone in
patients
with
rheumatoid
arthritis
with a
suboptimal
response
to
sulfasalazine:
results
from the
double-blind
placebo-controlled
MASCOT
study.
Annals
of the
Rheumatic
Diseases.
2007;66(2):235–241.
70
Allaart
CF,
Goekoop-Ruiterman
YP, De
Vries-Bouwstra
JK et
al.
Aiming
at low
disease
activity
in
rheumatoid
arthritis
with
initial
combination
therapy
or
initial
monotherapy
strategies:
the BeSt
study.
Clinical
&
Experimental
Rheumatology.
2006;24(6
suppl
43):1–77.
71
Goekoop-Ruiterman
YP, de
Vries
BJK,
Allaart
CF et
al.
Comparison
of
treatment
strategies
in early
rheumatoid
arthritis:
a
randomized
trial.
Ann
Intern
Med.
2007;146(6):406–415.
72
Goekoop-Ruiterman
YP, De
Vries-Bouwstra
JK,
Allaart
CF et
al.
Clinical
and
radiographic
outcomes
of four
different
treatment
strategies
in
patients
with
early
rheumatoid
arthritis
(the
best
study):
A
randomized,
controlled
trial.
Arthritis
&
Rheumatism.
2005;52(11):3381–3390.
73
Van der
Kooji
SM, De
Vries-Bouwstra
JK,
Goekoop-Ruiterman
YP et
al.
Limited
efficacy
of
conventional
DMARDs
after
initial
methotrexate
failure
in
patients
with
recent
onset
rheumatoid
arthritis
treated
according
to the
disease
activity
score.
Annals
of the
Rheumatic
Diseases.
2007;66(10):1356–1362.
74
Ferraccioli
GF,
Gremese
E,
Tomietto
P et al.
Analysis
of
improvements,
full
responses,
remission
and
toxicity
in
rheumatoid
patients
treated
with
step-up
combination
therapy
(methotrexate,
cyclosporin
A,
sulphasalazine)
or
monotherapy
for
three
years.
Rheumatology.
2002;41(8):892–898.
75
Choy
EH,
Smith
CM,
Farewell
V et al.
Factorial
randomised
controlled
trial of
glucocorticoids
and
combination
disease
modifying
drugs in
early
rheumatoid
arthritis.
Annals
of the
Rheumatic
Diseases.2008;67(5):656–663.
76
Braun J,
Kastner
P,
Flaxenberg
P et al.
Comparison
of the
clinical
efficacy
and
safety
of
subcutaneous
versus
oral
administration
of
methotrexate
in
patients
with
active
rheumatoid
arthritis:
results
of a
six-month,
multicenter,
randomized,
double-blind,
controlled,
phase IV
trial.
Arthritis
&
Rheumatism.
2008;58(1):
73–81.
77
Hider
SL,
Silman
A, Bunn
D et al.
Comparing
the
long-term
clinical
outcome
of
treatment
with
methotrexate
or
sulfasalazine
prescribed
as the
first
disease-modifying
antirheumatic
drug in
patients
with
inflammatory
polyarthritis.
Annals
of the
Rheumatic
Diseases.
2006;65(11):1449–1455.
78
Aetna.
Remicade:
Clinical
Policy
Document.
28
October
2005.
0341
Revised.
79
Keystone
E.
Reality-based
algorithm
for
treating
with
biologics.
Paper
presented
at: TNF
inhibitors:
A new
era in
the
treatment
of
rheumatoid
arthritis,
2005;
Vienna,
Austria.
80
Smolen
JS, Han
C, Bala
M et al.
ATTRACT
Study
Group.
Evidence
of
radiographic
benefit
of
treatment
with
infliximab
plus
methotrexate
in
rheumatoid
arthritis
patients
who had
no
clinical
improvement.
Arthritis
Rheum
2005;52:1020–30.
81
Keystone
EC,
Kavanaugh
AF,
Sharp JT
et al.
Radiographic,
clinical,
and
functional
outcomes
of
treatment
with
adalimumab
(a human
anti-tumor
necrosis
factor
monoclonal
antibody)
in
patients
with
active
rheumatoid
arthritis
receiving
concomitant
methotrexate
therapy.
Arthritis
Rheum
2004;50:1400–11.
82
Klareskog
L, van
der
Heijde
D, de
Jager JP
et al.
TEMPO
(Trial
of
etanercept
and
methotrexate
with
radiographic
patient
outcomes)
study
investigators.
Therapeutic
effect
of the
combination
of
etanercept
and
methotrexate
compared
with
each
treatment
alone in
patients
with
rheumatoid
arthritis:
double-blind
randomized
controlled
trial.
Lancet
2004;363:675–81.
83
Maini
RN,
Breedveld
FC,
Kalden
JR et
al.
Anti-Tumor
Necrosis
Factor
Trial in
Rheumatoid
Arthritis
with
Concomitant
Therapy
Study
Group.
Sustained
improvement
over two
years in
physical
function,
structural
damage,
and
signs
and
symptoms
among
patients
with
rheumatoid
arthritis
treated
with
infliximab
and
methotrexate.
Arthritis
Rheum
2004;50:1051–65.
84
Tak
et al.,
EULAR
2009,
Abstract
OP-0022
85
Rigby et
al.,
EULAR
2009,
Abstract
SAT0121
86
Higashida
J, Wun
T,
Schmidt
S,
Naguwa
SM,
Tuscano
JM.
Safety
and
efficacy
of
rituximab
in
patients
with
rheumatoid
arthritis
refractory
to
disease
modifying
antirheumatic
drugs
and
anti-tumor
necrosis
factor-alpha
treatment.
J
Rheumatol.
2005;
32:
2109-15.
87
Emery P,
Rigby W,
Combe B,
et al.
Efficacy
and
Safety
of
Rituximab
(RTX) as
First-Line
Biologic
Therapy
in
Patients
(pts)
with
Active
Rheumatoid
Arthritis
(RA):
Results
of a
Phase
III
Randomized
Controlled
Study
(SERENE).
Available
at
88
Cohen
SB,
Emery P,
Greenwald
MW, et
al; for
the
REFLEX
Trial
Group.
Rituximab
for
rheumatoid
arthritis
refractory
to
anti–tumor
necrosis
factor
therapy:
results
of a
multicenter,
randomized,
double-blind,
placebo-controlled,
phase
III
trial
evaluating
primary
efficacy
and
safety
at
twenty-four
weeks.
Arthritis
Rheum.
2006;54(9):2793-2806.
89
Keystone
E, Emery
P,
Peterfy
CG, et
al.
Prevention
of joint
structural
damage
at 1
year
with
rituximab
in
rheumatoid
arthritis
patients
with an
inadequate
response
to one
or more
TNF
inhibitors
(REFLEX
study)
[abstract
OP0016].
Ann
Rheum
Dis.
2006;65(suppl
II):58.
90
Luggen
M, Emery
P, Li T,
McCann
T, Teng
J,
Schiff
M.
Abatacept
provided
clinically
meaningful
improvements
in
multiple
aspects
of
health
related
quality
of life
(HRQoL)
and
physical
function
through
2 years
of
treatment
in
patients
with
active
rheumatoid
arthritis
(RA):
results
from the
AIM and
ATTAIN
trials.
Poster
presentation
Monday,
November
13,
2006,
Poster
no 980
at:
American
College
of
Rheumatology
annual
scientific
meeting.
Washington
DC,
November
10-15,
2006.
91
Dougados
M,
Russell
A, Li T,
Sherrer
Y, Teng
J,
McCann
T,
Westhovens
R.
Abatacept
provides
sustained
improvements
in pain,
fatigue
and
sleep
quality
through
2 years
in the
treatment
of
rheumatoid
arthritis
patients
in the
AIM and
ATTAIN
trials.
Poster
presentation
Sunday,
November
12,
2006,
poster
no 502
at:
American
College
of
Rheumatology
annual
scientific
meeting.
Washington
DC,
November
10-15,
2006.
92
Genovese
M,
Schiff
M,Luggen
M,
Becker
J-C,
Aranda
R,
McCann
T,Schmidely
N, Le
Bars M,
Dougados
M,
Sustained
Efficacy
and
Safety
Through
2 Years
in
Patients
with
Rheumatoid
Arthritis
in the
Long-term
Extension
of the
ATTAIN
Trial.
Poster
presentation
Sunday,
November
12,
2006,
Poster
no 498
at:
American
College
of
Rheumatology
annual
scientific
meeting.
Washington
DC,
November
10-15,
2006.
93
Weinblatt,
B Combe,
C
Birbara,
A
Covucci,
T Li,
J-C
Becker,
R Aranda,
E
Keystone.
Safety
and
Patient-reported
Outcomes
Through
2 Years
of
Treatment
with
Abatacept
in
Rheumatoid
Arthritis
Patients
Receiving
Background
Disease-modifying
Antirheumatic
Drugs (DMARDs):
The
ASSURE
Trial.
Poster
presentation
Sunday,
November
12,
2006,
poster
no 509
at:
American
College
of
Rheumatology
annual
scientific
meeting.
Washington
DC,
November
10-15,
2006.
94
Genovese
MC,
Becker
JC,
Schiff
M,
Luggen
M,
Sherrer
Y,
Kremer
J, et
al.
Abatacept
for
rheumatoid
arthritis
refractory
to tumor
necrosis
factor
alpha
inhibition.
N Engl J
Med.
2005;353:1114-23.
95
Maini
RN,
Taylor
PC,
Szechinski
J,
Pavelka
K, Broll
J,
Balint
G,et al,
for the
CHARISMA
Study
Group.
Double-blind
randomized
2978
GENOVESE
ET AL
controlled
clinical
trial of
the
interleukin-6
receptor
antagonist,
tocilizumab,
in
European
patients
with
rheumatoid
arthritis
who had
an
incomplete
response
to
methotrexate.
Arthritis
Rheum
2006;54:2817–29.
96
Nishimoto
N,
Hashimoto
J,
Miyasaka
N,
Yamamoto
K, Kawai
S,
Takeuchi
T, et
al.
Study of
active
controlled
monotherapy
used for
rheumatoid
arthritis,
an IL-6
inhibitor
SAMURAI):
evidence
of
clinical
and
radiographic
benefit
from an
x ray
reader-blinded
randomised
controlled
trial of
tocilizumab.
Ann
Rheum
Dis
2007;66:1162–7.
97
Nishimoto
N,
Yoshizaki
K,
Miyasaka
N,
Yamamoto
K, Kawai
S,
Takeuchi
T, et
al.
Treatment
of
rheumatoid
arthritis
with
humanized
anti–interleukin-6
receptor
antibody:
a
multicenter,
doubleblind,
placebo-controlled
trial.
Arthritis
Rheum
2004;50:1761–9.
98
Smolen
JS,
Beaulieu
A,
Rubbert-Roth
A,
Ramos-Remus
C,
Rovensky
J,
Alecock
E, et
al.
Effect
of
interleukin-6
receptor
inhibition
with
tocilizumab
in
patients
with
rheumatoid
arthritis
(OPTION
study):
a
double-blind,
placebo-controlled,
randomized
trial.
Lancet
2008;371:989–97.
99
Mark C.
Genovese,
James D.
McKay,
Evgeny
L.
Nasonov,et
al.
Interleukin-6
Receptor
Inhibition
With
Tocilizumab
Reduces
Disease
Activity
in
Rheumatoid
Arthritis
With
Inadequate
Response
to
Disease-Modifying
Antirheumatic
Drugs.
Arthritis
Rheum
2008;58:2968-2980
100
Emery P,
Keystone
E, Tony
HP,
Cantagrel
A, Van
Vollenhoven
R,
Sánchez
A.
IL-6
receptor
inhibition
with
tocilizumab
improves
treatment
outcomes
in
patients
with
rheumatoid
arthritis
refractory
to anti-tumour
necrosis
factor
biologicals:
Results
from a
24-week
multicentre
randomised
placebo-controlled
trial.
Ann
Rheum
Dis.
2008;67:1516-1523.
101
Jones G,
Gu JR,
Lowenstein
M.
Tocilizumab
monotherapy
is
superior
to
methotrexate
monotherapy
in
reducing
disease
activity
in
patients
with
rheumatoid
arthritis:
The
AMBITION
study.
Ann
Rheum
Dis.
2008;67:89.
102
Kremer
JM,
Fleischmann
RM,
Halland
AM,
Brzezicki
J,
Woodworth
T,
Fisheleva
E.
Tocilizumab
inhibits
structural
joint
damage
in
rheumatoid
arthritis
patients
with an
inadequate
response
to
methotrexate:
The
LITHE
study.
Arthritis
Rheum.
2008;58:L11.
103
Keane J,
Gershon
S, Wise
RP,
Mirabil-Levens
E,
Kasznica
J,
Schwiterman
WD, et
al.
Tuberculosis
associated
with
infliximab,
a tumor
necrosis
factor
alpha-neutralizing
agent. N
Engl J
Med.
2001;345:1098-104.
104
Gomez-Reino
JJ,
Carmona
L,
Rodriguez-Valverde
V,
Martin-Mola
E,
Moreno
C, et
al, on
behalf
of the
BIOBADASER
Group.
An
active
surveillance
of
rheumatoid
arthritis
patients
treated
with
tumor
necrosis
factor
inhibitors
indicates
significant
tuberculosis
risk
increase.
Arthritis
Rheum.
2003;48:2122-7.
105
F.
Tubach,
D.
Salmon,
P.
Ravaud,
et al.
Risk of
Tuberculosis
Is
Higher
With
Anti–Tumor
Necrosis
Factor
Monoclonal
Antibody
Therapy
Than
With
Soluble
Tumor
Necrosis
Factor
Receptor
Therapy.
Arth and
Rheum
2009:60;1884-1894
106
Grupo de
Trabajo
sobre
Tuberculosis.
Consenso
nacional
para el
control
de la
Tuberculosis
en
España.
Med Clin
(Barc).
1992;98:24-31.
107
Grupo de
Trabajo
del área
TIR de
SEPAR.
Recomendaciones
SEPAR.
Normativa
sobre la
prevención
de la
tuberculosis.
Arch
Bronconeumol.
2002;38:441-51.
108
American
Thoracic
Society.
Targeted
tuberculin
testing
and
treatment
of
latent
tuberculosis
infection.
Am J
Respir
Crit
Care Med.
2000;161:S221-
47 (update
2001;
164:
1319-1320.)
109
Carmona
L,
Gomez-Reino
JJ,
Rodriguez-Valverde
V,
Montero
D,
Pascual-Gomez
E, Mola
EM, et
al.
Effectiveness
of
recommendations
to
prevent
reactivation
of
latent
tuberculosis
infection
in
patients
treated
with
tumor
necrosis
factor
antagonists.
Arthritis
Rheum.
2005;52:1766-72.
110
Mohan N,
Edwards
ET,
Cupps TR,
Oliverio
PJ,
Sanberg
G,
Crayton
H, et
al.
Demyelination
occurring
during
anti-tumor
necrosis
factor a
therapy
for
infflammatory
arthritides.
Arthritis
Rheum.
2001;44:2862-9.
111
Wolfe F,
Michaud
K.
Lymphoma
in
rheumatoid
arthritis:
the
effect
of
methotrexate
and
anti-tumor
necrosis
factor
therapy
in
18,572
patients.
Arthritis
Rheum.
2004;50:1740-51.
112
Geborek
P,
Bladstrom
A,
Turesson
C, Gulfe
A,
Petersson
IF,
Saxne T,
et al.
Tumour
necrosis
factor
blockers
do not
increase
overall
tumour
risk in
patients
with
rheumatoid
arthritis,
but may
be
associated
with an
increased
risk of
lymphomas.
Ann
Rheum
Dis.
2005;64:699-703.
113
Hyrich
KL,
Silman
AJ,
Watson
KD,
Symmons
DP.
Anti-tumour
necrosis
factor
alpha
therapy
in
rheumatoid
arthritis:
an
update
on
safety.
Ann
Rheum
Dis.
2004;63:1538-43.
114
Kimby E.
Tolerability
and
safety
of
rituximab
(MabThera).
Cancer
Treat
Rev.
2005;31:456-73.
114
Kavanaugh
AF.
Anti-tumor
necrosis
factor-alpha
monoclonal
antibody
therapy
for
rheumatoid
arthritis.
Rheum
Dis Clin
North Am
1998;24:593–614.
115
Furst
DE,
Keystone
E, Maini
RN,
Smolen
JS.
Recapitulation
of the
round-table
discussion—assessing
the role
of
anti-tumor
necrosis
factor
therapy
in the
treatment
of
rheumatoid
arthritis.
Rheumatology
1999;38(suppl
2):50–3.
116
Lipsky
PE, van
der
Heijde
DM, St
Clair EW
et al.
Infliximab
and
methotrexate
in the
treatment
of
rheumatoid
arthritis.
Anti-Tumor
Necrosis
Factor
Trial in
Rheumatoid
Arthritis
with
Concomitant
Therapy
Study
Group. N
Engl J
Med
2000;343:1594–602.
117
Furst
DE,
Schiff
MH,
Fleischmann
RM et
al.
Adalimumab,
a fully
human
anti
tumor
necrosis
factor-alpha
monoclonal
antibody,
and
concomitant
standard
antirheumatic
therapy
for the
treatment
of
rheumatoid
arthritis:
results
of STAR
(Safety
Trial of
Adalimumab
in
Rheumatoid
Arthritis).
J
Rheumatol
2003;30:2563–71.
118
Cheifetz
A,
Smedley
M,
Martin S
et al.
The
incidence
and
management
of
infusion
reactions
to
Infliximab:
a large
center
experience.
Am J
Gastroenterol
2003;98:1315–24.
119
Jarvis
B,
Faulds
D.
Etanercept:
a review
of its
use in
rheumatoid
arthritis.
Drugs
1999;57:945–66.
120
Hochberg
MC,
Tracy JK,
Hawkins-Holt
M,
Flores
RH.
Comparison
of the
efficacy
of the
tumour
necrosis
factor
alpha
blocking
agents
adalimumab,
etanercept
and
Infliximab
when
added to
methotrexate
in
patients
with
active
rheumatoid
arthritis.
Ann
Rheum
Dis
2003;62(suppl
2):ii13–ii16.
121
Flendrie
M,
Creemers
MC,
Welsing
PM, den
Broeder
AA, van
Riel PL.
Survival
during
treatment
with
tumour
necrosis
factor
blocking
agents
in
rheumatoid
arthritis.
Ann
Rheum
Dis
2003;62(suppl
2):
ii30–ii33.
122
van
Vollenhoven
R, Harju
A,
Brannemark
S,
Klareskog
L.
Treatment
with
infliximab
(Remicade)
when
etanercept
(Enbrel)
has
failed
or vice
versa:
data
from the
STURE
registry
showing
that
switching
tumour
necrosis
factor
alpha
blockers
can make
sense.
Ann
Rheum
Dis
2003;62:1195–8.
123
Ang
HT,
Helfgott
S. Do
the
clinical
responses
and
complications
following
etanercept
or
infliximab
therapy
predict
similar
outcomes
with the
other
tumor
necrosis
factor-alpha
antagonists
in
patients
with
rheumatoid
arthritis?
J
Rheumatol
2003;30:2315–18.
124
Buch
MH,
Bingham
SJ, Seto
Y et al.
Switching
biologics
after
initial
anti-tumour
necrosis-a
failure:
success
with
further
TNF-a
antagonism
but
failure
on
subsequent
interleukin-1
receptor
antagonism.
Rheumatology
2004;
43(suppl
2):37.
125
Bennett
AN,
Peterson
P, Banya
N et al.
Adalimumab
in
clinical
practice—initial
experience
at a
single
UK
center.
Rheumatology
2004;43(suppl
2):37.
126
Wick
MC,
Lindblad
S,
Klareskog
L, Van
Vollenhoven
RF.
Adalimumab
restores
clinical
response
in
patients
who have
lost
response
to
infliximab
(Remicade)
or
Etanercept
(Enbrel):
Data
from the
STURE
registry.
Ann
Rheum
Dis
2004;63(suppl
1): 260.
127
Van
der Bijl
AE,
Breedveld
FC,
Antoni C
et al.
Infliximab
failures
in
rheumatoid
arthritis
can be
successfully
treated
with
Adalimumab
(Humira).
Ann
Rheum
Dis
2004;63(suppl):264.
128
Brocq O,
Albert
CC, Roux
CH et
al.
Adalimumab
in
severe
rheumatoid
arthritis
after
failure
of one
or two
anti-TNF:
18
patients.
Ann
Rheum
Dis
2004;63(suppl
1):531.
129
Feltelius
N, Fored
M,
Blomqvist
P et al.
Safety
and
efficacy
of
adalimumab
in
arthritis
patients
previously
treated
with
another
biologic
agent.
Ann
Rheum
Dis
2004;63
(suppl
1):304.
130
Kiely
PDW,
Johnson
DM.
Infliximab
and
leflunomide
combination
therapy
in
rheumatoid
arthritis:
an open
label
study.
Rheumatology
2003;41:631–7.
131
Durez P,
Nzeusseu
A,
Dufour
JP,
Derogelaer
JP,
Houssiau
FA.
Treatment
of
severe
refractory
Ra with
a
combination
of
infliximab
and
azathioprine:
one year
results
of an
open
label
pilot
study.
Ann
Rheum
Dis
2002;61:abstract
FRI0140.
132
Weinblatt
ME,
Kremer
JM,
Bankhurst
AD et
al. A
trial of
etanercept,
a
recombinant
tumor
necrosis
factor
receptor:Fc
fusion
protein,
in
patients
with
rheumatoid
arthritis
receiving
methotrexate.
N Engl J
Med
1999;340:253–9.
133
Klareskog
L, van
der
Heijde
D, de
Jager JP
et al.
Therapeutic
effect
of the
combination
of
etanercept
and
methotrexate
compared
with
each
treatment
alone in
patients
with
rheumatoid
arthritis:
double-blind
randomised
controlled
trial.
Lancet
2004;363:675–81.
134
Khanna
M,
Shirodkar
MA,
Gottlieb
AB.
Etanercept
therapy
in
patients
with
autoimmunity
and
hepatitis
C. J
Dermatol
Treat
2003;14:229–32.
135
Prior P,
Symmons
DP,
Hawkins
CF,
Scott
DL,
Brown R.
Cancer
morbidity
in
rheumatoid
arthritis.
Ann
Rheum
Dis
1984;43:128–31.
136
Isomaki
HA,
Hakulinen
T,
Joutsenlahti
U.
Excess
risk of
lymphomas,
leukemia
and
myeloma
in
patients
with
rheumatoid
arthritis.J
Chronic
Dis
1978;31:691–6.
137
Baecklund
E, Ekbom
A,
Sparen
P,
Feltelius
N,
Klareskog
L.
Disease
activity
and risk
of
lymphoma
in
patients
with
rheumatoid
arthritis:
nested
case-control
study.
Br Med J
1998;317:180–1.
138
Markham
A, Lamb
HM.
Infliximab:
a review
of its
use in
the
management
of
rheumatoid
arthritis.
Drugs
2000;59:1341–59.
139
Kavanaugh
AF.
Anti-tumor
necrosis
factor-alpha
monoclonal
antibody
therapy
for
rheumatoid
arthritis.
Rheum
Dis Clin
North Am
1998;24:593–614.
140
Jarvis
B,
Faulds
D.
Etanercept:
a review
of its
use in
rheumatoid
arthritis.
Drugs
1999;57:945–66.
141
Baert F,
Noman M,
Vermeire
S et al.
Influence
of
immunogenicity
on the
long-term
efficacy
of
Infliximab
in
Crohn’s
disease.
N Engl J
Med
2003;348:601–8.
142
Debandt
M,
Vittecoq
O,
Descamps
V, Le
Loet X,
Meyer O.
Anti-
TNF-alpha-induced
systemic
lupus
syndrome.
Clin
Rheumatol
2003;22:56–61.
143
De Rycke
L,
Kruithof
E, Van
Damme N
et al.
Antinuclear
antibodies
following
Infliximab
treatment
in
patients
with
rheumatoid
arthritis
or
spondyloarthropathy.
Arthritis
Rheum
2003;48:1015–23.
144
Louis M,
Rauch J,
Armstrong
M,
Fitzcharles
MA.
Induction
of
autoantibodies
during
prolonged
treatment
with
Infliximab.
J
Rheumatol
2003;30:2557–62.
145
Lepore
L,
Marchetti
F,
Facchini
S, Leone
V,
Ventura
A.
Druginduced
systemic
lupus
erythematosus
associated
with
etanercept
therapy
in a
child
with
juvenile
idiopathic
arthritis.
Clin Exp
Rheumatol
2003;21:276–7.
146
Swale VJ,
Perrett
CM,
Denton
CP,
Black
CM,
Rustin
MH.
Etanercept-induced
systemic
lupus
erythematosus.
Clin Exp
Dermatol
2003;28:604–7.
143
Carlson
E,
Rothfield
N.
Etanercept-induced
lupus-like
syndrome
in a
patient
with
rheumatoid
arthritis.
Arthritis
Rheum
2003;48:1165–6.
144
Esteve-Vives
J,
Batlle-Gualda
E, Reig
A, Grupo
para la
Adaptación
del HAQ
a la
Población
Española.
Spanish
version
of the
Health
Assessment
Questionnaire
(HAQ):
reliability,
validity
and
transcultural
equivalency.
J
Rheumatol.
1993;20:2116-22.
145
Van
der
Heijde
DM,
Dankert
T,
Nieman
F, Rau
R, Boers
M.
Reliability
and
sensitivity
to
change
of a
simplification
of the
Sharp/van
der
Heijde
radiological
assessment
in
rheumatoid
arthritis.
Rheumatology.
1999;38:941-7.
146
Lard
LR,
Visser
H,
Speyer
I, Van
der
Horst-Bruinsman
IE,
Zwinderman
AH,
Breedveld
FC, et
al.
Early
versus
delayed
treatment
in
patients
with
recent-onset
rheumatoid
arthritis:
comparison
of two
cohorts
who
received
different
treatment
strategies.
Am J
Med.
2001;111:446-51.
147
Nell
VPK,
Machold
KP,
Eberl G,
Stamm
TA,
Uffmann
M,
Smolen
JS.
Benefit
of very
early
referral
and very
early
therapy
with
disease-modifying
anti-rheumatic
drugs in
patients
with
very
early
rheumatoid
arthritis.
Rheumatolology.
2004;43:906-14.
148
Quinn
MA,
Conaghan
PG,
Emery P.
The
therapeutic
approach
of early
intervention
for
rheumatoid
arthritis:
what is
the
evidence?
Rheumatology.
2001;40:1211-20.
149
Boers M.
Understanding
the
window
of
opportunity
concept
in early
rheumatoid
arthritis
(review).
Arhritis
Rheum.
2003;48:1771-4.
150
Goekoop-Ruiterman
YP, De
Vries-Bouwstra
JK,
Allaart
CF, Van
Zeben D,
Kersten
PJSM,
Hazes
JMW, et
al.
Clinical
and
radiographic
outcomes
of four
different
treatment
strategies
in
patients
with
early
rheumatoid
arthritis
(the
BeSt
study):
a
randomized,
controlled
trial.
Arthritis
Rheum.
2005;52:3381-90.
151
Ferrero
S, Ragni
N.
Inflammatory
bowel
disease:
management
issues
during
pregnancy.
Arch
Gynecol
Obstet
2004;270:79–85
(Epub
2003 30
April).
152
Burt MJ,
Frizelle
FA,
Barbezat
GO.
Pregnancy
and
exposure
to
Infliximab
(anti-tumor
necrosis
factor-alpha
monoclonal
antibody).
J
Gastroenterol
Hepatol
2003;18:465–6.
153
Chakravarty
EF,
Sanchez-Yamamoto
D, Bush
TM. The
use of
disease
modifying
antirheumatic
drugs in
women
with
rheumatoid
arthritis
of
childbearing
age: a
survey
of
practice
patterns
and
pregnancy
outcomes.
J
Rheumatol
2003;30:241–6.
Updated
BSR
guidelines
for
prescribing
anti-TNF
in
adults
with RA
163
154
Slifman
NR,
Gershon
SK, Lee
JH,
Edwards
ET,
Braun
MM.
Listeria
monocytogenes
infection
as a
complication
of
treatment
with
tumor
necrosis
factor
alpha-neutralizing
agents.
Arthritis
Rheum
2003;48:319–24.
155
De Rosa
FG, Shaz
D,
Campagna
AC,
Dellaripa
PE,
Khettry
U,
Craven
DE.
Invasive
pulmonary
aspergillosis
soon
after
therapy
with
Infliximab,
a tumor
necrosis
factor-alpha-neutralizing
antibody:
a
possible
healthcare-associated
case?
Infect
Control
Hosp
Epidemiol
2003;24:477–82.
156
Kroesen
S,
Widmer
AF,
Tyndall
A,
Hasler
P.
Serious
bacterial
infections
in
patients
with
rheumatoid
arthritis
under
anti-TNF-alpha
therapy.
Rheumatology
2003;42:617–21.
157
Furst
DE,
Schiff
MH,
Fleischmann
RM et
al.
Adalimumab,
a fully
human
anti
tumor
necrosis
factor-alpha
monoclonal
antibody,
and
concomitant
standard
antirheumatic
therapy
for the
treatment
of
rheumatoid
arthritis:
results
of STAR
(Safety
Trial of
Adalimumab
in
Rheumatoid
Arthritis).
J
Rheumatol
2003;30:2563–71.
158
Hanauer
SB.
Review
article:
safety
of
Infliximab
in
clinical
trials.
Aliment
Pharmacol
Ther
1999;13(suppl
4):16–22.
159
Doran
MF,
Crowson
CS, Pond
GR,
O’Fallon
WM,
Gabriel
SE.
Frequency
of
infection
in
patients
with
rheumatoid
arthritis
compared
with
controls:
a
population-based
study.
Arthritis
Rheum
2002;46:2287–93.
160
Doran
MR,
Crowson
CS, Pond
GR,
O’Fallon
WM,
Gabriel
SE.
Predictors
of
infection
in
rheumatoid
arthritis.
Arthritis
Rheum
2002;46:2294–300.
161
Brocq O,
Plubel
Y,
Breuil
V,
Grisot
C, Flory
P,
Mousnier
A, et
al.
Etanercept
-
infliximab
switch
in
rheumatoid
arthritis
14 out
of 131
patients
treated
with
anti TNF.
alpha.
Presse
Med.
2002;31:1836-9.
162
Hansen
KE,
Hildebrand
JP,
Genovese
MC, Cush
JJ,
Patel S,
Cooley
DA, et
al.
The
efficacy
of
switching
from
etanercept
to
infliximab
in
patients
with
rheumatoid
arthritis.
J
Rheumatol.
2004;31:1098-102.
163
Vollenhoven
RF,
Gullstrom
E,
Brannemark
S,
Klareskog
L. Dose
escalation
of
infliximab
in
clinical
practice:
Data
from the
Stockholm
TNF
registry.
Arthritis
Rheum.
2001;44
Suppl:S82.
164
Uhlig T,
Smedstad
LM,
Vaglum
P. The
course
of
rheumatoid
arthritis
and
predictors
of
psychological,physical
and
radiographic
outcome
after 5
years of
follow-up.
Rheumatology.
2000;39(7):732–741.
165
Wolfe F,
Sharp
JT.
Radiographic
outcome
of
recent-onset
rheumatoid
arthritis.
A
19-year
study of
radiographic
progression.
Arthritis
&
Rheumatism.
1998;41(9):1571–1582.
166
Young A,
Bielawska
C,
Corbett
M et al.
A
prospective
study of
early
onset
rheumatoid
arthritis
over
fifteen
years:
prognostic
features
and
outcome.
Clinical
Rheumatology.
1987;6(suppl
2):12–19.
167
Bukhari
M, Lunt
M,
Harrison
BJ et
al.
Rheumatoid
factor
is the
major
predictor
of
increasing
severity
of
radiographic
erosions
in
rheumatoid
arthritis:
results
from the
Norfolk
Arthritis
Register
Study, a
large
inception
cohort.
Arthritis
&
Rheumatism.
2002;46(4):906–912.
168
Forslind
K,
Ahlmen
M,
Eberhardt
K et al.
Prediction
of
radiological
outcome
in early
rheumatoid
arthritis
in
clinical
practice:
Role of
antibodies
to
citrullinated
peptides
(anti-CCP).
Annals
of the
Rheumatic
Diseases.
2004;63(9):1090–1095.
169
Kroot EJ,
De Jong
B, Van
Leeuwen
MA et
al.
The
prognostic
value of
anti-cyclic
citrullinated
peptide
antibody
in
patients
with
recent-onset
rheumatoid
arthritis.
Arthritis
&
Rheumatism.
2000;43(8):1831–1835.
170
Linn-Rasker
SP, Van
der
Helm-van
Mil AH,
Breedveld
FC et
al.
Arthritis
of the
large
joints –
in
particular,
the knee
– at
first
presentation
is
predictive
for a
high
level of
radiological
destruction
of the
small
joints
in
rheumatoid
arthritis.
Annals
of the
Rheumatic
Diseases.
2007;66(5):646–650.
171
Priolo
F,
Bacarini
L,
Cammisa
M et al.
Radiographic
changes
in the
feet of
patients
with
early
rheumatoid
arthritis.
GRISAR (Gruppo
Reumatologi
Italiani
Studio
Artrite
Reumatoide).
Journal
of
Rheumatology.
1997;24(11):2113–2118.
172
Ronnelid
J, Wick
MC,
Lampa J
et al.
Longitudinal
analysis
of
citrullinated
protein/peptide
antibodies
(anti-CP)
during 5
year
follow
up in
early
rheumatoid
arthritis:
anti-CP
status
predicts
worse
disease
activity
and
greater
radiological
progression.
Annals
of the
Rheumatic
Diseases.
2005;64(12):1744–1749.
173
Van
Jaarsveld
CH, ter
Borg EJ,
Jacobs
JW et
al. The
prognostic
value of
the
antiperinuclear
factor,
anticitrullinated
peptide
antibodies
and
rheumatoid
factor
in early
rheumatoid
arthritis.
Clinical
&
Experimental
Rheumatology.
1999;17(6):689–697.
174
Dixey J,
Solymossy
C, Young
A. Is it
possible
to
predict
radiological
damage
in early
rheumatoid
arthritis
(RA)? A
report
on the
occurrence,
progression,
and
prognostic
factors
of
radiological
erosions
over the
first 3
years in
866
patients
from the
early RA
study
(ERAS).
Journal
of
Rheumatology.
2004;31(suppl
69):
48–54.
175
Forslind
K,
Hafstrom
I,
Ahlmen M
et al.
Sex: a
major
predictor
of
remission
in early
rheumatoid
arthritis?
Annals
of the
Rheumatic
Diseases.
2007;66(1):46–52.
176
Wolfe F,
Ross K,
Hawley
DJ et
al. The
prognosis
of
rheumatoid
arthritis
and
undifferentiated
polyarthritis
syndrome
in the
clinic:
a study
of 1141
patients.
Journal
of
Rheumatology.
1993;20(12):2005–2009.
177
Odegard
S,
Landewe
R, van d
et al.
Association
of early
radiographic
damage
with
impaired
physical
function
in
rheumatoid
arthritis:
A
ten-year,
longitudinal
observational
study in
238
patients.
Arthritis
&
Rheumatism.
2006;54(1):68–75.
178
Leigh
JP,
Fries JF.
Predictors
of
disability
in a
longitudinal
sample
of
patients
with
rheumatoid
arthritis.
Annals
of the
Rheumatic
Diseases.
1992;51(5):581–587.
179
Sherrer
YS,
Bloch
DA,
Mitchell
DM et
al.
Disability
in
rheumatoid
arthritis:
comparison
of
prognostic
factors
across
three
populations.
Journal
of
Rheumatology.
1987;14(4):705–709.
180
Wolfe F,
Zwillich
SH. The
long-term
outcomes
of
rheumatoid
arthritis:
a
23-year
prospective,
longitudinal
study of
total
joint
replacement
and its
predictors
in 1,600
patients
with
rheumatoid
arthritis.
Arthritis
&
Rheumatism.
1998;41(6):1072–1082.
181
Strating
MM, Van
Schuur
WH,
Suurmeijer
TP.
Predictors
of
functional
disability
in
rheumatoid
arthritis:
results
from a
13-year
prospective
study.
Disability
&
Rehabilitation.
2007;29(10):805–815.
182
Sihvonen
S,
Korpela
M,
Mustila
A et al.
The
predictive
value of
rheumatoid
factor
isotypes,
anti-cyclic
citrullinated
peptide
antibodies,
and
antineutrophil
cytoplasmic
antibodies
for
mortality
in
patients
with
rheumatoid
arthritis.
Journal
of
Rheumatology.
2005;32(11):2089–2094. |
